QBiotics

Harnessing the power of nature to improve lives

About

The QBiotics Group (QBiotics) is an unlisted, public, Australian life sciences company specialising in the discovery and development of novel cell signalling small molecules. QBiotics applies phenotypic screening to generate breakthrough innovation in the discovery of first in class solutions to challenging medical conditions. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds.

QBiotics’ lead oncology drug, tigilanol tiglate, is currently in human clinical Phase II trials in Soft Tissue Sarcoma and Head and Neck Cancer. Tigilanol tiglate has received Orphan Drug Designation from the US FDA for the treatment of Soft Tissue Sarcomas. A veterinary formulation of tigilanol tiglate is registered and marketed as a veterinary oncology pharmaceutical, under the trade name STELFONTA^®, in Australia, the USA, Europe, and the UK.

QBiotics’ lead wound healing drug candidate, EBC 1013, is a small molecule targeting a range of wounds, including chronic and acute wounds and burns. A first-in-human Phase I clinical development in patients with venous leg ulcers is open for recruitment.

Dedicated to the discovery and development of novel cell signalling small molecules derived from nature

Watch:

Watch Dr. Victoria Gordon reflecting on QBiotics’ 25 years of operation

Products:

STELFONTA® (tigilanol tiglate)

Tigilanol tiglate, branded as STELFONTA®*, is approved and marketed as a veterinary pharmaceutical for treatment of non-metastatic, canine mast cell tumours(^1,2) in the United States of America, European Union, Switzerland, United Kingdom and Australia.

European Medicines Agency (2020).STELFONTA^®.

STELFONTA^® (tigilanol tiglate injection) packaging insert (2020)

European Medicines Agency. (2020).STELFONTA^®.